{
    "symbol": "NUWE",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-08 11:52:05",
    "content": " Penetration of our ambulatory clinical treating heart failure patients, continued development of clinical data supporting the Aquadex systems, clinical and economic value, and a steady progress on our new product pipeline such as our product, our pediatric continuous renal replacement therapy device. In the past, most of the clinical studies that we have -- that we have so far on the therapy have signaled benefits and improvements using the Aquadex, but with the avoid heart failure, the new data proves that indeed there is a significant benefits, statistical superior benefit, as you say of using the Aquadex and removing fluid overload especially in heart failure patients that are unresponsive to direct."
}